Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
Laurus Labs Ltd. is a leading research-driven pharmaceutical and biotechnology company. It was founded in the year 2005 by Dr. Satyanarayana Chava. The company has grown to become a significant player in the global pharmaceutical industry. The headquarters of the company is located in Hyderabad, Telangana. Laurus Lab's main products include active pharmaceutical ingredients (APIs), generic formulations, and speciality ingredients. The company also offers contract development and manufacturing organization (CDMO) services. Laurus Labs falls under the pharmaceutical and biotechnology sector. It has a strong market presence in the pharmaceutical industry. Read More...
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 5,067.17 | 6,046.55 | 4,950.87 | 4,837.17 | 2,837.64 |
Total Expenses | 4,830.81 | 4,937.61 | 3,867.02 | 3,536.06 | 2,544.03 |
Profit Before Tax | 236.36 | 1,108.94 | 1,083.85 | 1,301.11 | 293.61 |
Profit After Tax | 168.21 | 796.64 | 832.43 | 983.82 | 255.27 |
Operating Profit after Depreciation | 419.26 | 1,274.11 | 1,186.24 | 1,369.27 | 383.20 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 3,890.01 | 3,408.62 | 2,652.47 | 2,170.62 | 1,726.34 |
Total Non Current Assets | 4,552.06 | 4,198.72 | 3,623.43 | 2,675.83 | 1,938.26 |
Total Current Assets | 3,834.97 | 3,461.68 | 3,344.61 | 3,074.86 | 1,812.06 |
TOTAL ASSETS | 8,387.03 | 7,660.40 | 6,968.04 | 5,750.69 | 3,750.32 |
Total Shareholder's Fund | 4,110.95 | 4,037.53 | 3,351.19 | 2,597.55 | 1,769.77 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 665.69 | 993.90 | 911.10 | 733 | 347.42 |
Net Cash used in Investing Activities | -822.25 | -996.94 | -914.47 | -940.93 | -221.04 |
Net Cash used in Financing Activities | 249.83 | -26.64 | 30.26 | 254.70 | -127.66 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 4,859.81 | 5,789.40 | 4,728.59 | 4,796.04 | 2,803.15 |
Total Expenses | 4,558.34 | 4,737.97 | 3,753.18 | 3,521.41 | 2,498.67 |
Profit Before Tax | 301.47 | 1,051.43 | 975.41 | 1,274.63 | 304.48 |
Profit After Tax | 223.70 | 760.38 | 750.09 | 956.11 | 267.05 |
Operating Profit after Depreciation | 452.29 | 1,197.13 | 1,071.27 | 1,340.55 | 392.19 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 3,036.31 | 2,884.16 | 2,186.23 | 1,818.04 | 1,694.18 |
Total Non Current Assets | 4,150.37 | 3,786.70 | 3,403.96 | 2,583.74 | 1,954.72 |
Total Current Assets | 3,517.11 | 3,171.26 | 3,204.57 | 3,041.45 | 1,784.64 |
TOTAL ASSETS | 7,667.48 | 6,957.96 | 6,608.53 | 5,625.19 | 3,739.36 |
Total Shareholder's Fund | 4,207.05 | 4,056.82 | 3,388.21 | 2,712.24 | 1,815.80 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 658.54 | 881.55 | 822.97 | 694.45 | 344.68 |
Net Cash used in Investing Activities | -756.74 | -735.27 | -836.61 | -899.68 | -216.83 |
Net Cash used in Financing Activities | 139.41 | -185.19 | 15.19 | 243.13 | -127.48 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 1,415.05 | 1,223.70 | 1,194.91 | 1,439.67 | 1,194.92 |
Total Expenses | 1,129.90 | 1,045.37 | 1,023.71 | 1,198.18 | 1,013.50 |
Profit Before Tax | 130.68 | 22.81 | 18.46 | 107.27 | 34.62 |
Profit After Tax | 90.61 | 17.72 | 12.21 | 75.32 | 25.17 |
Operating Profit after Depreciation | 294.57 | 182.93 | 173.71 | 260.02 | 183.85 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 1,265.19 | 1,184.85 | 1,116.93 | 1,414.52 | 1,132.19 |
Total Expenses | 1,058.91 | 1,003.02 | 955.54 | 1,143.41 | 961.81 |
Profit Before Tax | 76.72 | 58.09 | 38.80 | 164.31 | 56.70 |
Profit After Tax | 57.27 | 42.44 | 28.78 | 121.32 | 42.64 |
Operating Profit after Depreciation | 213.40 | 193.72 | 170.69 | 295.20 | 181.10 |
₹0.4/Share
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Laurus Labs Ltd | ₹546.55 | ₹29,467.75 |
Sun Pharmaceuticals Industries Ltd | ₹1,704.65 | ₹4,09,002.64 |
Divis Laboratories Ltd | ₹5,836.45 | ₹1,54,939.41 |
Cipla Ltd | ₹1,459.05 | ₹1,17,834.93 |
Torrent Pharmaceuticals Ltd | ₹3,011.50 | ₹1,01,918.27 |
Dr Reddys Laboratories Ltd | ₹1,195.85 | ₹99,784.59 |
Laurus Labs Ltd is quoting at Rs 546.75, down 9.03% on the day as on 13:19 IST on the NSE. The stock jumped 39.28% in last one year as compared to a 4.2% rally in NIFTY and a 11.87% spurt in the Nifty Pharma index.
14 Feb 2025, 01:35 pm
Laurus Labs Ltd is quoting at Rs 638.45, up 1.16% on the day as on 12:49 IST on the NSE. The stock is up 60.15% in last one year as compared to a 7.61% jump in NIFTY and a 18.78% jump in the Nifty Pharma index.
06 Feb 2025, 01:06 pm
Laurus Labs Ltd is quoting at Rs 585.45, up 3.11% on the day as on 12:49 IST on the NSE. The stock is up 46.75% in last one year as compared to a 9.94% gain in NIFTY and a 26.31% gain in the Nifty Pharma index.
20 Jan 2025, 01:06 pm
On 24 January 2025
07 Jan 2025, 10:07 am
Laurus Labs Ltd is quoting at Rs 590.25, up 0.61% on the day as on 12:44 IST on the NSE. The stock is up 36.3% in last one year as compared to a 9.49% gain in NIFTY and a 37.53% gain in the Nifty Pharma.
30 Dec 2024, 01:00 pm
View More